Understand any stock in simple English
Enter a ticker to learn what the company does and how it makes money.
IQVIA helps drug companies run clinical trials and gives them data and software to understand how medicines are used and sold.
IQVIA is a company that helps the drug industry figure out what works and what sells. Drugmakers hire it to run clinical trials — the human tests that prove a medicine is safe and effective before regulators will approve it. Those trials are slow, expensive, and full of paperwork, so a company with people and software already in place can do the job faster than building a trial team from scratch. IQVIA also sells something less obvious: data. It gathers information on prescriptions, sales, and patient trends in many countries and packages it into reports and software that help drugmakers decide what to study, where to sell, and how to price their products.
The business is really two big chunks wearing one name. One is the research side, where IQVIA designs and runs trials for drug companies, biotech firms, and medical-device makers — a service it got much bigger at by buying the contract research firm Quintiles, which then merged with IMS Health in 2016 to create IQVIA as it exists today. The other is the data and analytics side, a modern version of IMS Health's old market-research business. That side behaves a bit like a subscription service: customers keep paying for fresh data and software because the information is only useful if it stays current and covers a lot of the market. Together they form a one-stop shop, so a client can buy both the advice and the machinery to test and sell a new drug. The customers are big pharmaceutical companies, smaller biotech firms, and medical-device makers, and they come back again and again because switching data providers or trial operators is a hassle. Competitors include other contract research organizations, like Charles River Laboratories and ICON, and data players such as Clarivate and Veeva on the software side. IQVIA's edge is scale and breadth — it operates in many countries and its data pool gets more valuable as it grows, which makes it hard for a newcomer to copy. One real vulnerability is cost discipline: running global trials is labor-heavy, and the company has spent years cutting its own overhead to keep margins healthy while carrying a large debt load from its mergers.
For a company its size, IQVIA is fairly quiet about its cash. It tends to put money toward paying down the debt that came with its big deals, and it has returned cash to shareholders. Investors have bought back stock over the years, though the buybacks have not shrunk the share count by anything worth making a fuss over. The honest summary: this is a toll collector on the long, expensive road from lab idea to pharmacy shelf, and it earns its money by being the easiest, broadest option rather than the cheapest one.
Saved answer · last researched 22 Oct 2026